Sean T. Smith
Analyst · Krish Sankar with Bank of America Merrill Lynch
Thanks, Deno, and good morning, everyone. I'll provide a brief analysis of our financial results for the fourth quarter of fiscal year 2012, review our balance sheet and cash flows, and then provide our outlook for the first quarter of 2013. For purposes of our discussions, I will be primarily comparing our non-GAAP operating results to the revised fourth quarter guidance we published in our October 31, 2012, press release. Please refer to Slide 5 for our GAAP to non-GAAP net income and EPS reconciliation as we review the first quarter -- fourth quarter. During the quarter, we did incur a minor charge of about $200k related to a Singapore consolidation. Slide 6, 7, and 8 show our sequential, quarterly and year-to-date IC and FPD performance. Fourth quarter revenue decreased by 10.6% sequentially to $104.2 million as a result of the general softness Deno discussed for both for IC and FPD photomasks. During the quarter, we experienced sequential declines for both high-end and mainstream IC and FPD photomasks. Revenues for IC and FPD photomasks were $83.9 million and $20.3 million, respectively, for the fourth quarter of 2012. Breaking out sales geographically, 60% of total sales were from Asia, 31% from North America and 9% from Europe. High-end global IC sales were $23.6 million or 28% of total IC sales for the quarter. This represents a sequential decrease of $3.8 million. Global mainstream sales decreased sequentially by $2.6 million or 4%. Advanced FPD sales were $11.7 million or 58% of total FPD sales. As a reminder, high-end IC revenues consist of revenue derived from semi designed at and below 45 nanometers and high-end FPD revenues consist of revenue at and above G8, as well as AMOLED-based products. Now let's continue through the income statement. Gross margin for the fourth quarter was 23.3%, which was down 440 basis points sequentially as a result of decreased sales. The 23.3% gross margin for the fourth quarter was actually higher than our Q1 2012 gross margin when we had revenues nearly 8% higher at $112 million. Selling, general and administrative expenses for the fourth quarter were $11.4 million, down sequentially by $400,000 or 3%. Research and development expenses, which consists principally of continued development for our global advanced process technologies and qualifications of advanced nodes, were $5.3 million. During the last 6 months of 2012, we experienced increased qualifications for which we should benefit us in 2013. Please turn to Slide 9. During the quarter, we generated operating income excluding the consolidation charge of $7.6 million or 7.3% of sales. EBITDA, as defined in our credit agreement for the fourth quarter, was $28 million and for the year amounted to $135 million. Also, for the year, free cash flow was $63 million, which is EBITDA of $135 million less nonfinanced cash CapEx of $72 million. Other income and expense for the fourth quarter was expense of $1.6 million, which was up about $900,000 sequentially due principally to unfavorable foreign exchange. During the quarter, we recorded a tax provision of $1.6 million. GAAP net income was $3.8 million or $0.06 per diluted share and non-GAAP net income was $4.1 million or $0.07 per diluted share. At the end of the fourth quarter, we had approximately 1,292 full-time employees. And this equates to revenue per employee of $323,000 on an annualized basis. For fiscal 2012, our headcount decreased by 58 or 4%. Now turning to the balance sheet. Despite missing our initial guidance and decreased sequential operating results, our balance sheet actually improved quarter-over-quarter. Cash and cash equivalents at the year end amounted to $218 million and our net cash was $41 million or up $22 million sequentially. Our working capital at the end of the quarter was $233 million, which was up $21 million compared to Q3 2012. Diligent inventory management and, to a lesser extent, improved AR returns, contributed to this improvement. Accounts payable and accrued current liabilities at year end amounted to $79 million. And at the end of Q4 2012, $7 million of CapEx was accrued for. Please turn to Slide 10 as we review our capitalization. Total debt at year end was $177 million. The principal components of outstanding debt include: $22 million of a 5.5% senior unsecured convertible notes, which are due in October of 2014; $115 million 3.25% senior convertible unsecured notes due in April of 2016; approximately $15 million for capital lease obligation; $24 million, 2.5% 5-year term loan related to the nanoFab building; and approximately $1 million related to an obligation with a customer who co-funded a tool purchase. At the end of the fiscal 2012, we do not have any outstanding borrowings on our $30 million revolving credit line, which matures in April of 2015. Taking a look at our cash flows. Cash provided by operations for the fourth quarter was approximately $25 million. And depreciation and amortization was $20.2 million. For fiscal 2012, cash provided by operations was $133 million. Cash flow used in investing activities during Q4 amounted to approximately $5 million and was $112 million for the whole year of 2012. Fiscal 2012 cash used in investing activities includes $72 million of cash CapEx, a $25 million loan on the nanoFab building and $13 million of increased investment in our joint venture. Net cash used by financing activities during the quarter amounted to $5 million and includes $4 million related to the repurchase of PSMC shares. During fiscal 2012, we increased our ownership in PSMC from 62% to 72%. Please turn to Slide 11, as we take a look ahead. We expect our cash CapEx needs for 2012 to be in the range of $70 million to $90 million. We do, however, have the flexibility to accelerate or decelerate our spend depending upon market conditions. We do expect to continue generate free cash flow once again in 2013. And our 2013 investments will principally be geared towards high-end, leading-edge products for IC and FPD applications. The significant high-end increases in market share gains we have seen over the past few years have certainly validated our high-end investment strategy. Our visibility, as always, continues to be limited as our backlog is typically 1 to 2 weeks. For Q1, we do expect to experience some reduced orders related to the year-end holiday season. We also expect to continue to see a somewhat muted market overall for IC and FPD products. So taking this all into consideration, we are projecting revenue for the first quarter of 2013 to be in the range of $96 million to $100 million. During 2013, our tax rate will be impacted by the flow of income from jurisdictions for which we may have credits and upon our limited ability to recognize tax benefits in areas which we are taxable. For the first quarter of fiscal 2013, this will equate to a range $1 million to $2 million in whole dollar terms. For fiscal 2013, we estimate total taxes will range from $11 million to $13 million. As a result, based upon our current operating model, we estimate earnings per share for the first quarter to be the in range of breakeven to $0.03 per share. Please turn to Slide 11. In summary, I'll leave you with a few key thoughts. First, we continue to expect to generate free cash flow in 2013. Second, we are confident about our business model and our ability to weather any short-term softness in the market while continuing to grow our market share at the high end. We see continued opportunities in our customers' businesses and node migration plan and we have a strong financial position and excellent technology to capitalize on those plans. And finally, we expect to continue to build on the momentum that we have established over the past few years as a leader in advanced photomask technology. Although our visibility is limited as always, we plan to match our operating infrastructure to the market environment. Now I'd like to turn the call over to the operator for questions and answers.